For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | |
| Research and development | 1,681 | 4,292 | 3,054 | |
| General and administrative | 3,811 | 2,579 | 2,555 | |
| Total operating expenses | 5,492 | 6,871 | 5,609 | |
| Loss from operations | -5,492 | -6,871 | -5,609 | |
| Other income, net | -89 | 49 | 108 | |
| Net loss | -5,581 | -6,822 | -5,501 | |
| Unrealized (loss) gain on investments, net of tax of 0 | 0 | 12 | -45 | |
| Foreign currency translation adjustments | 0 | -24 | 31 | |
| Total other comprehensive gain (loss) | 0 | -12 | -14 | |
| Total comprehensive loss | -5,581 | -6,834 | -5,515 | |
| Earnings per share, basic | -0.21 | -0.28 | -0.25 | |
| Earnings per share, diluted | -0.21 | -0.28 | -0.25 | |
| Weighted average common shares outstanding - basic | 26,361,386 | 24,187,536 | 21,915,891 | |
| Weighted average common shares outstanding - diluted | 26,361,386 | 24,187,536 | 21,915,891 | |
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)